138 related articles for article (PubMed ID: 2182424)
1. Intensive induction therapy with behenoyl, cytosine arabinoside, daunorubicin, and 6-mercaptopurine followed by intensive consolidation with mitoxantrone, etoposide, vincristine, and intermediate-dose continuous cytarabine (M-85 protocol) for adult acute myelogenous leukemia.
Ohno R; Yokomaku S; Okumara M; Tanimoto M; Morishita Y; Morishima Y; Kodera Y; Saito H
Haematol Blood Transfus; 1990; 33():304-8. PubMed ID: 2182424
[No Abstract] [Full Text] [Related]
2. Consolidation therapy with high-dose cytosine arabinoside: experiences of a prospective study in acute myeloid leukemia.
Kurrle E; Ehninger G; Fackler-Schwalbe E; Freund M; Heil G; Hoelzer D; Link H; Löffler B; Lösch A; Mitrou PS
Haematol Blood Transfus; 1990; 33():254-60. PubMed ID: 2182418
[No Abstract] [Full Text] [Related]
3. Intensive sequential chemotherapy for children with acute myelogenous leukemia.
Grier HE; Gelber RD; Clavell LA; Camitta BM; Link MP; Garcea MJ; Weinstein HJ
Haematol Blood Transfus; 1990; 33():193-7. PubMed ID: 2182411
[No Abstract] [Full Text] [Related]
4. Mitoxantrone and etoposide in patients with relapsed and refractory acute nonlymphocytic leukemia.
Rowe JM; Mazza JJ; Hines JD; Cassileth PA; Oken MM; Bennett JM; Andersen J
Haematol Blood Transfus; 1990; 33():326-9. PubMed ID: 2182427
[No Abstract] [Full Text] [Related]
5. Proposal for the classification of relapsed and refractory acute myeloid leukemias as the basis for an age-adjusted randomized comparison of sequentially applied high-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone (S-HAM).
Hiddemann W; Aul HC; Maschmeyer G; Urbanitz D; Lathan B; Reichle A; Köppler H; Donhuijsen-Ant R; Ludwig WD; Grüneisen T
Haematol Blood Transfus; 1990; 33():604-10. PubMed ID: 2182450
[No Abstract] [Full Text] [Related]
6. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia.
Jehn U; Heinemann V
Haematol Blood Transfus; 1990; 33():333-8. PubMed ID: 1691134
[TBL] [Abstract][Full Text] [Related]
7. Acute nonlymphocytic leukemia in adults: results obtained with TAD remission induction therapy.
Witteveen EO; Verdonck LF; Nieuwenhuis HK; Dekker AW
Haematol Blood Transfus; 1990; 33():309-13. PubMed ID: 2323635
[No Abstract] [Full Text] [Related]
8. A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group.
Jehn U; Zittoun R; Suciu S; Fiere D; Haanen C; Peetermans M; Löwenberg B; Willemze R; Solbu G; Stryckmans P
Haematol Blood Transfus; 1990; 33():277-84. PubMed ID: 1691132
[TBL] [Abstract][Full Text] [Related]
9. A multicentre study on intensive induction and consolidation therapy in acute myelogenous leukaemia.
Kurrle E; Ehninger G; Freund M; Heil G; Hoelzer D; Link H; Mitrou PS; Ohl S; Queisser W; Schlimok G
Blut; 1988 May; 56(5):233-6. PubMed ID: 3285914
[No Abstract] [Full Text] [Related]
10. High-dose Ara-C as a single-agent consolidation therapy in childhood acute myelogenous leukemia.
Lie SO; Berglund G; Gustafsson G; Jonmundsson G; Siimes M; Yssing M
Haematol Blood Transfus; 1990; 33():215-21. PubMed ID: 2138994
[No Abstract] [Full Text] [Related]
11. [Intensive induction chemotherapy of adult acute myelogenous leukemia by continuing daunorubicin, behenoyl-cytosine arabinoside, 6-mercaptopurine and prednisolone until marrow aplasia].
Taguchi H; Kubonishi I; Takehara N; Uemura Y; Iwahara Y; Eguchi T; Miyagi T; Sugito S; Muneishi H; Tanaka Y
Gan To Kagaku Ryoho; 1992 Aug; 19(9):1309-14. PubMed ID: 1503485
[TBL] [Abstract][Full Text] [Related]
12. MEC (mitoxantrone, etoposide and intermediate dose cytarabine): an effective induction regimen for previously untreated acute non-lymphocytic leukemia.
Visani G; Petti MC; Cenacchi A; Manfroi S; Tosi P; Spadea A; Latagliata R; Amadori S; Mandelli F; Tura S
Leuk Lymphoma; 1995 Nov; 19(5-6):447-51. PubMed ID: 8590845
[TBL] [Abstract][Full Text] [Related]
13. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
[TBL] [Abstract][Full Text] [Related]
14. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.
Arlin Z; Case DC; Moore J; Wiernik P; Feldman E; Saletan S; Desai P; Sia L; Cartwright K
Leukemia; 1990 Mar; 4(3):177-83. PubMed ID: 2179638
[TBL] [Abstract][Full Text] [Related]
15. Treatment of childhood acute nonlymphocytic leukemia: cooperative Austrian-Hungarian study AML-IGCI-84.
Fink FM; Gadner H; Grümayer ER; Kardos G; Revesz T; Urban C; Mutz I; Ausserer B; Schuler D
Haematol Blood Transfus; 1990; 33():233-6. PubMed ID: 2182415
[No Abstract] [Full Text] [Related]
16. Intensive individualized induction therapy with behenoyl cytarabine, daunorubicin and 6-mercaptopurine followed by intensive consolidation including intermediate-dose continuous cytarabine, mitoxantron, etoposide and vinca alkaloids in acute myeloid leukemia in adults.
Ohno R; Yokomaku S; Okumura M; Nagai T; Kitaori K; Ito T; Takeo T; Sugiura I; Yano K; Ito Y
Int J Hematol; 1991 Dec; 54(6):487-93. PubMed ID: 1793832
[TBL] [Abstract][Full Text] [Related]
17. [A short duration treatment with intensive consolidation therapy for patients with acute myelogenous leukemia--13 year experience in a single institute].
Fujiwara M; Satou N; Izumi N; Shibasaki Y; Higashimura M; Tsukada N; Koike T
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1793-8. PubMed ID: 18030012
[TBL] [Abstract][Full Text] [Related]
18. Remission induction and postremission therapy in acute myelogenous leukemia: British MRC Study.
Rees JK; Gray RG
Haematol Blood Transfus; 1990; 33():243-8. PubMed ID: 1691131
[No Abstract] [Full Text] [Related]
19. Combination of mitoxantrone and etoposide in patients aged over 60 years with untreated acute myelogenous leukemia.
Ehninger G; Fackler-Schwalbe E; Freund M; Heil G; Henke M; Hoelzer D; Hoffmann R; Kurrle E; Link H; Lösch A
Haematol Blood Transfus; 1990; 33():316-7. PubMed ID: 2182425
[No Abstract] [Full Text] [Related]
20. Therapy of childhood acute myelogenous leukemia: an update of the AIEOP/LAM 8204 study. Italian Pediatric Hematology-Oncology Association.
Amadori S; Ceci A; Comelli A; Madon E; Masera G; Nespoli L; Paolucci G; Zanesco L; Vegna ML; Moleti ML
Haematol Blood Transfus; 1990; 33():222-5. PubMed ID: 2182413
[No Abstract] [Full Text] [Related]
[Next] [New Search]
